Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), AstraZeneca plc (ADR) (AZN) Round 2; START

 The pharmaceutical industry was the focus of intense debate earlier this year owing to potential merger between Pfizer Inc. (NYSE:PFE) and AstraZeneca plc (ADR) (NYSE:AZN). With the six month cooling period coming to its close, the question that looms in the minds of many is whether another bid is on its way to AstraZeneca’s door?

Pfizer Inc. (NYSE:PFE)

CNBC‘s Catherine Boyle discussed this possibility. She pointed out that a lot has changed in the past six months, since  Pfizer Inc. (NYSE:PFE)’s first offer, but when it’s about the largest pharmaceutical company in the world, nothing is set in stone.

“[…] It [AstraZeneca plc (ADR) (NYSE:AZN)] is less attractive than it was 6 months ago. That tax inversion reason has been taken out of the multiplier. They have also made a deal with Merck, which means that they are going to have access to some of the Immuno-Oncology drugs, the new kind of cancer treatment, which had been one of the real factors behind a potential AstraZeneca deal, and on the other hand one of the other potential companies that Pfizer Inc. (NYSE:PFE) might bid for would have been Actavis, which is now off the table […],” said Boyle.

The core issue is that  Pfizer Inc. (NYSE:PFE) needs acquisition or even acquisitions to plug a hole in its drugs pipeline. As is usually the case in the pharmaceutical industry, smaller promising concerns get bought by the larger companies. The deal is a mutually beneficial one, since they benefit from the large pockets and better distribution channels of the bigger company while a giant like Pfizer Inc. (NYSE:PFE) gets to add some much needed new drugs in its portfolio.

The pertinent question is that is the deal with Merck & Co., Inc. (NYSE:MRK) goint to satiate Pfizer’s hunger? With AstraZeneca plc (ADR) (NYSE:AZN) in its pocket, the pharmaceutical giant could diversify its risks and land a greater chance of dominating the Immuno-Oncology scene, which is expected to grow upto $35 billion annually over the next decade, according to Citigroup.

Video Embed Size: 530 X 298 640 X 360

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.